8.1.5: Other antineoplastic drugs

Part of chapter 8 Malignant Disease and Immunosuppression, section 8.1 Cytotoxic drugs

High-level prescribing trends for Other antineoplastic drugs (BNF section 8.1.5) across Wyre Integrated Network LTD PCN for the last five years. You can explore prescribing trends for this section by Sub-ICB Location, or learn more about this site.

View all matching dm+d items.

No prescriptions found.

Do you need help with your analysis? Don't forget to check the FAQ page, and get in touch if you have questions.

Chemicals

Abemaciclib (0801050CL)
Afatinib (0801050BP)
Arsenic (0801050AI)
Axitinib (0801050BJ)
Bexarotene (0801050AB)
Bosutinib (0801050BL)
Cabozantinib (0801050BR)
Carboplatin (0801050F0)
Celecoxib (0801050AY)
Dasatinib (0801050AN)
Docetaxel (0801050D0)
Encorafenib (0801050CM)
Erlotinib (0801050AE)
Everolimus (0801050AX)
Gefitinib (0801050AW)
Hydroxycarbamide (0801050P0)
Ibrutinib (0801050BS)
Imatinib mesilate (0801050AA)
Lapatinib (0801050AT)
Midostaurin (0801050CK)
Mitotane (0801050R0)
Nilotinib (0801050AS)
Nintedanib (0801050BT)
Niraparib (0801050CJ)
Olaparib (0801050BY)
Osimertinib (0801050CG)
Paclitaxel (0801050V0)
Palbociclib (0801050CB)
Pazopanib (0801050AZ)
Pipobroman (0801050BH)
Ponatinib (0801050BQ)
Procarbazine hydrochloride (0801050U0)
Ribociclib (0801050CR)
Ruxolitinib (0801050BI)
Sorafenib (0801050AJ)
Sunitinib (0801050AM)
Temozolomide (0801050Y0)
Topotecan (0801050AF)
Trametinib (0801050CH)
Trastuzumab (0801050AD)
Tretinoin (0801050X0)
Vandetanib (0801050BG)
Feedback